Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6654738 | 0.87 | CXCR4 (0.42) | CXCR4CNR2TGM2 | |
| SCHEMBL6651838 | 0.87 | CXCR4 (0.43) | CXCR4CNR2TGM2MITFOPRM1 | |
| SCHEMBL6652671 | 0.86 | CXCR4 (0.44) | CXCR4CNR2TGM2MITFOPRM1 | |
| SCHEMBL6657754 | 0.82 | CXCR4 (0.41) | CXCR4CNR2METAP2METAP1 | |
| SCHEMBL6018231 | 0.82 | FOLH1 (0.41) | TGM2 | |
| SCHEMBL6652095 | 0.81 | CXCR4 (0.60) | CXCR4TGM2METAP2METAP1 | |
| SCHEMBL6658361 | 0.79 | CXCR4 (0.40) | CXCR4CNR2METAP2METAP1 | |
| SCHEMBL6018396 | 0.79 | TGM2 (0.37) | CXCR4TGM2 | |
| SCHEMBL6652792 | 0.78 | CXCR4 (0.58) | CXCR4TGM2METAP2METAP1 | |
| SCHEMBL6694422 | 0.77 | FOLH1 (0.47) | CNR2TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254221-A1 | Novel Nitrogenous Compound and use thereof | KUREHA CORPORATION (JP) | 2004-12-16 | — | — | US | claimed |
| EP-1431290-A1 | NOVEL NITROGENOUS COMPOUND AND USE THEREOF | Kureha Chemical Industry Co., Ltd. (JP) | 2004-06-23 | — | — | EP | claimed |
| US-20040254221-A1 | Novel Nitrogenous Compound and use thereof | KUREHA CORPORATION (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1431290-A1 | NOVEL NITROGENOUS COMPOUND AND USE THEREOF | Kureha Chemical Industry Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254221-A1 | Novel Nitrogenous Compound and use thereof | NGLY1, NOD1, CCR1 | CXCR4 88/4885CNR2 932/4885TGM2 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.